Cantor Fitzgerald Lowers Earnings Estimates for MannKind

Key Points

• Cantor Fitzgerald has lowered its FY2026 earnings per share estimate for MannKind Corporation from $0.24 to $0.14, which is below the consensus estimate of $0.10.
• MannKind reported a quarterly earnings per share of $0.05, surpassing the expected $0.04, although its revenue of $76.53 million fell short of the projected $77.82 million.
• Despite mixed analyst ratings and a consensus price target of $9.71, the company has had significant institutional investment activity, including 200% increase in holdings by Quaker Wealth Management LLC during the second quarter.

MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2026 earnings per share (EPS) estimates for shares of MannKind in a research note issued to investors on Thursday, August 7th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will earn $0.14 per share for the year, down from their previous forecast of $0.24. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. The company had revenue of $76.53 million for the quarter, compared to analysts' expectations of $77.82 million. MannKind had a net margin of 10.87% and a negative return on equity of 28.33%. MannKind's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.05 earnings per share.

MNKD has been the subject of several other research reports. Wall Street Zen lowered MannKind from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Mizuho started coverage on MannKind in a research report on Thursday, April 10th. They set an "outperform" rating and a $12.00 target price on the stock. Royal Bank Of Canada lowered their price target on MannKind from $8.00 to $7.00 and set an "outperform" rating for the company in a research report on Thursday. Finally, HC Wainwright upgraded shares of MannKind to a "buy" rating and set a $9.00 price objective on the stock in a research report on Wednesday, July 16th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $9.71.

MannKind Stock Performance

Shares of NASDAQ:MNKD traded up $0.07 on Friday, reaching $3.50. The company's stock had a trading volume of 678,882 shares, compared to its average volume of 2,338,902. The company has a 50-day simple moving average of $3.88 and a 200 day simple moving average of $4.65. MannKind has a 52-week low of $3.40 and a 52-week high of $7.63. The company has a market cap of $1.06 billion, a P/E ratio of 31.68 and a beta of 1.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quaker Wealth Management LLC increased its holdings in MannKind by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 14,000 shares during the period. Farther Finance Advisors LLC grew its stake in MannKind by 1,379.2% in the second quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 6,896 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in MannKind in the fourth quarter worth about $37,000. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of MannKind during the second quarter valued at about $42,000. Finally, Master S Wealth Management Inc. bought a new stake in shares of MannKind in the 2nd quarter valued at about $44,000. 49.55% of the stock is currently owned by institutional investors.

Insider Activity at MannKind

In other MannKind news, Director Steven B. Binder sold 75,367 shares of the company's stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $3.94, for a total value of $296,945.98. Following the completion of the sale, the director directly owned 830,508 shares in the company, valued at approximately $3,272,201.52. This represents a 8.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Thomson sold 32,179 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total value of $150,597.72. Following the transaction, the executive vice president owned 772,427 shares in the company, valued at approximately $3,614,958.36. This represents a 4.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 266,198 shares of company stock valued at $1,143,244 in the last ninety days. Insiders own 2.70% of the company's stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.